Action ARWR ARROWHEAD PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Arrowhead Pharmaceuticals, Inc.

Actions

ARWR

US04280A1007

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/06/2024 		Varia. 5j. Varia. 1 janv.
26,26 USD -2,27 % Graphique intraday de Arrowhead Pharmaceuticals, Inc. +11,39 % -14,18 %
25/06 Arrowhead Pharmaceuticals prévoit d'avancer son médicament expérimental Plozasiran dans une étude cardiovasculaire de stade avancé MT
25/06 Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial
Sector Update: Health Care Stocks Advance Monday Afternoon
Arrowhead Says Potential Obesity Treatment Shows 'Promising' Preclinical Results -- Shares Rise
Arrowhead Pharmaceuticals : American Diabetes Association (ADA) 84th Scientific Sessions View Presentation
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals : TIDES USA 2024 TIDES 2024 AdiposeTIDES 2024 ARO-SOD1
Arrowhead Pharmaceuticals : 2024 Second Quarter Results Prepared Remarks
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARWR
  4. Actualités Arrowhead Pharmaceuticals, Inc.
  5. Autres langues